PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.

The Company intends to use the net proceeds of the Offering to evaluate and pursue potential strategic transactions, including the identification, due diligence, and negotiation of one or more acquisitions, business combinations, or other transactions that may constitute a “Significant Transaction” under the policies of the Canadian Securities Exchange (the “Exchange”). Pending such transactions, proceeds may also be used for general and administrative expenses, maintaining the Company’s listing status, and general working capital purposes.

The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals.

The securities issued pursuant to the Offering will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. In the event the Company undertakes a transaction that constitutes a fundamental change, change of business, reverse takeover, or other reviewable transaction as defined under applicable securities laws and Exchange policies, the resale restrictions may extend beyond four months and one day following the completion of such transaction. There can be no assurance that any transaction will be identified or completed, and the Company may reallocate the use of proceeds depending on evolving business needs and market conditions.

ABOUT PSYENCE GROUP: www.psyence.com

Psyence is a life science biotechnology company listed on the Canadian Securities Exchange (CSE: PSYG), with a focus on natural psychedelics. Psyence works with nature-derived psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.